MedTrace Logo

Listener Training for Improved Intelligibility of People With Parkinson's Disease

NCT06815263 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-04-23

No results posted yet for this study

Summary

Listener training offers a promising avenue for improving communication for people with dysarthria due to Parkinson's disease by offsetting the intelligibility burden from the patient onto their primary communication partners. Here, we employ a repeated-measures, randomized controlled trial to establish the efficacy of listener training for patients with PD and their primary communication partners. This translational work will establish a new realm of clinical practice in which the intelligibility impairments in PD are addressed by training partners to better understand dysarthric speech, thus elevating communication outcomes and participation in daily life.

Conditions

  • Dysarthria, Hypokinetic

Interventions

BEHAVIORAL

Listener Training

Partner participants are presented with individual audio phrases that make up passage reading speech stimuli and orthographic transcriptions of what the patient is saying. Partners are asked to listen carefully to the audio files and use the written subtitles to help them understand what is being said.

Sponsors & Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • Florida State University

    collaborator OTHER

  • Utah State University

    lead OTHER

Principal Investigators

  • Stephanie Borrie, PhD · Utah State University

  • Kaitlin Lansford, PhD · Florida State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2029-01-01
Completion
2029-05-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06815263 on ClinicalTrials.gov